### General description

<table>
<thead>
<tr>
<th>INN</th>
<th>Doxycycline</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>J01AA02</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>Antibiotic groups</td>
<td>ACCESS</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1977 (TRS 615) for Bacterial infection of unspecified site  
Added in 1995 (TRS 867) for Malaria due to Plasmodium falciparum  
Added in 1999 (TRS 895) for Malaria due to Plasmodium falciparum  
Added in 2017 (TRS 1006) for Chronic obstructive pulmonary disease with acute exacerbation  
Added in 2017 (TRS 1006) for Cholera  
Added in 2017 (TRS 1006) for Bacterial pneumonia  
Added in 2017 (TRS 1006) for Chlamydia trachomatis  
Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site |

### Recommendations

<table>
<thead>
<tr>
<th>Wikipedia</th>
<th>Doxycycline</th>
</tr>
</thead>
<tbody>
<tr>
<td>DrugBank</td>
<td>Doxycycline</td>
</tr>
</tbody>
</table>
## Access group antibiotics

**Oral > Liquid:** 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

**Oral > Solid:** 50 mg (as hyclate); 100 mg (as hyclate)

**Parenteral > General injections > unspecified:** 100 mg in vial powder for injection

**Oral > Solid:** 100 mg (as hyclate); 50 mg (as hyclate)

**Oral > Solid:** 100 mg (as hyclate)

### Indications

**First choice**
- Chlamydia trachomatis
- Cholera

**Second choice**
- Cholera [children]
- Chronic obstructive pulmonary disease with acute exacerbation
- Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

**Other indications**
- Bacterial infection of unspecified site

---

## Antimalarial medicines > For curative treatment

**Oral > Solid:** 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

### Indications
- Malaria due to Plasmodium falciparum

---

## Antimalarial medicines > For chemoprevention

**Oral > Solid:** 100 mg (hydrochloride or hyclate)

### Indications
- Malaria due to Plasmodium falciparum